サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：クラミジア診断・治療の世界市場予測（2022年～2028年）
市場調査レポート
商品コード
1123178

クラミジア診断・治療の世界市場予測（2022年～2028年）

Global Chlamydia Diagnosis and Treatment Market Research and Forecast 2022-2028
出版日: | 発行: Orion Market Research | ページ情報: 英文 100 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
クラミジア診断・治療の世界市場予測（2022年～2028年）
出版日: 2022年07月25日
発行: Orion Market Research
ページ情報: 英文 100 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のクラミジア診断・治療の市場規模は、予測期間中に6.0%という大きなCAGRで成長すると予測されています。

ライフスタイルの変化が、市場に影響を与え促進する主要な要因の1つです。また、ポイントオブケア診断テストの採用拡大、政府によるクラミジア診断・治療に関する啓蒙活動なども、市場成長に大きく貢献する主要因と考えられます。しかし、STDの予防措置とともに、新興国における低い認知度が、世界のクラミジア診断・治療市場の成長を妨げる主要な抑制要因です。さらに、マイクロ流体診断などの技術進歩が、市場機会を生み出している主要な要因の1つです。

当レポートでは、世界のクラミジア診断・治療市場について調査分析し、市場概要、セグメント・地域別の市場分析、競合情勢、企業プロファイルなど、体系的な情報を提供しています。

目次

第1章 レポートの概要

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向

第3章 競合情勢

  • 主要企業分析
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の開発
  • 主要戦略分析
  • COVID-19が主要企業に与える影響

第4章 市場決定要因

  • 促進要因
  • 抑制要因
  • 機会

第5章 市場の内訳

  • 世界のクラミジア診断・治療市場：診断方法別
    • クラミジア培養
    • 尿培養
    • 酵素免疫測定法
    • 核酸増幅試験
  • 世界のクラミジア診断・治療市場：治療アプローチ別
    • 経口抗生物質
    • 注射剤
  • 世界のクラミジア診断・治療市場：エンドユーザー別
    • 病院
    • 診断センター
    • 研究機関

第6章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋
  • 世界のその他の地域

第7章 企業プロファイル

  • Abbott
  • Aetna Inc.
  • Anthem, Inc
  • binx health, inc.
  • Bio-Rad Laboratories, Inc.
  • DiaSorin S.p.A
  • Diazyme Laboratories, Inc.
  • Evofem Biosciences, Inc.
  • F. Hoffmann-La Roche Ltd
  • Hologic, Inc.
  • Laboratory Corporation of America
  • NURX Inc.
  • Quidel Corp.
  • Siemens
  • Synapse Diagnostics PVT LTD
  • Tosoh Corp.
  • Trinity Biotech
  • Thermo Fisher Scientific Inc.
図表

LIST OF TABLES

  • 1. GLOBAL CHLAMYDIA DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS, 2020-2027 ($ MILLION)
  • 2. GLOBAL CHLAMYDIA DIAGNOSIS AND TREATMENT MARKET BY DIAGNOSIS METHODS, 2020-2027 ($ MILLION)
  • 3. GLOBAL CHLAMYDIA CULTURE MARKET BY REGION, 2020-2027 ($ MILLION)
  • 4. GLOBAL URINE CULTURE MARKET BY REGION, 2020-2027 ($ MILLION)
  • 5. GLOBAL ENZYME IMMUNOASSAYS MARKET BY REGION, 2020-2027 ($ MILLION)
  • 6. GLOBAL NUCLEIC ACID AMPLIFICATION TEST MARKET BY REGION, 2020-2027 ($ MILLION)
  • 7. GLOBAL CHLAMYDIA DIAGNOSIS AND TREATMENT MARKET BY TREATMENT APPROACH, 2020-2027 ($ MILLION)
  • 8. GLOBAL ORAL ANTIBIOTICS MARKET BY REGION, 2020-2027 ($ MILLION)
  • 9. GLOBAL INJECTABLE MARKET BY REGION, 2020-2027 ($ MILLION)
  • 10. GLOBAL CHLAMYDIA DIAGNOSIS AND TREATMENT MARKET BY END-USER, 2020-2027 ($ MILLION)
  • 11. GLOBAL HOSPITALS MARKET BY REGION, 2020-2027 ($ MILLION)
  • 12. GLOBAL DIAGNOSTIC CENTRES MARKET BY REGION, 2020-2027 ($ MILLION)
  • 13. GLOBAL RESEARCH INSTITUTIONS MARKET BY REGION, 2020-2027 ($ MILLION)
  • 14. GLOBAL CHLAMYDIA DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027 ($ MILLION)
  • 15. NORTH AMERICAN CHLAMYDIA DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 16. NORTH AMERICAN CHLAMYDIA DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHODS, 2020-2027 ($ MILLION)
  • 17. NORTH AMERICA CHLAMYDIA DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS, BY TREATMENT APPROACH, 2017-2023($ MILLION)
  • 18. NORTH AMERICAN CHLAMYDIA DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
  • 19. EUROPEAN CHLAMYDIA DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 20. EUROPEAN CHLAMYDIA DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHODS, 2020-2027 ($ MILLION)
  • 21. EUROPEAN CHLAMYDIA DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT APPROACH, 2020-2027 ($ MILLION)
  • 22. EUROPEAN CHLAMYDIA DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
  • 23. ASIA-PACIFIC CHLAMYDIA DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 24. ASIA-PACIFIC CHLAMYDIA DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS, BY DIAGNOSIS METHODS, 2020-2027 ($ MILLION)
  • 25. ASIA-PACIFIC CHLAMYDIA DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS, BY TREATMENT APPROACH, 2020-2027 ($ MILLION)
  • 26. ASIA-PACIFIC CHLAMYDIA DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
  • 27. REST OF THE WORLD CHLAMYDIA DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHODS,2020-2027 ($ MILLION)
  • 28. REST OF THE WORLD CHLAMYDIA DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT APPROACH,2020-2027 ($ MILLION)
  • 29. REST OF THE WORLD CHLAMYDIA DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL CHLAMYDIA DIAGNOSIS AND TREATMENT MARKET, 2020-2027 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL CHLAMYDIA DIAGNOSIS AND TREATMENT MARKET SHARE BY SEGMENT, 2020-2027 ($ MILLION)
  • 3. RECOVERY OF GLOBAL CHLAMYDIA DIAGNOSIS AND TREATMENT MARKET, 2021-2027 (%)
  • 4. GLOBAL CHLAMYDIA DIAGNOSIS AND TREATMENT MARKET SHARE BY DIAGNOSIS METHODS, 2020 VS 2027 (%)
  • 5. GLOBAL CHLAMYDIA DIAGNOSIS AND TREATMENT MARKET SHARE BY TREATMENT APPROACH, 2020 VS 2027 (%)
  • 6. GLOBAL CHLAMYDIA DIAGNOSIS AND TREATMENT MARKET SHARE BY END-USER, 2020 VS 2027 (%)
  • 7. GLOBAL CHLAMYDIA DIAGNOSIS AND TREATMENT MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 8. GLOBAL CHLAMYDIA CULTURE MARKET BY REGION, 2020 VS 2027 (%)
  • 9. GLOBAL URINE CULTURE MARKET BY REGION, 2020 VS 2027 (%)
  • 10. GLOBAL ENZYME IMMUNOASSAYS MARKET BY REGION, 2020 VS 2027 (%)
  • 11. GLOBAL NUCLEIC ACID AMPLIFICATION TEST MARKET BY REGION, 2020 VS 2027 (%)
  • 12. GLOBAL ORAL ANTIBIOTICS MARKET BY REGION, 2020 VS 2027 (%)
  • 13. GLOBAL INJECTABLE MARKET BY REGION, 2020 VS 2027 (%)
  • 14. GLOBAL HOSPITALS MARKET BY REGION, 2020 VS 2027 (%)
  • 15. GLOBAL DIAGNOSTIC CENTRES MARKET BY REGION, 2020 VS 2027 (%)
  • 16. GLOBAL RESEARCH INSTITUTIONS MARKET BY REGION, 2020 VS 2027 (%)
  • 17. US CHLAMYDIA DIAGNOSIS AND TREATMENT MARKET SIZE, 2020-2027 ($ MILLION)
  • 18. CANADA CHLAMYDIA DIAGNOSIS AND TREATMENT MARKET SIZE, 2020-2027 ($ MILLION)
  • 19. UK CHLAMYDIA DIAGNOSIS AND TREATMENT MARKET SIZE, 2020-2027 ($ MILLION)
  • 20. FRANCE CHLAMYDIA DIAGNOSIS AND TREATMENT MARKET SIZE, 2020-2027 ($ MILLION)
  • 21. GERMANY CHLAMYDIA DIAGNOSIS AND TREATMENT MARKET SIZE, 2020-2027 ($ MILLION)
  • 22. ITALY CHLAMYDIA DIAGNOSIS AND TREATMENT MARKET SIZE, 2020-2027 ($ MILLION)
  • 23. SPAIN CHLAMYDIA DIAGNOSIS AND TREATMENT MARKET SIZE, 2020-2027 ($ MILLION)
  • 24. REST OF EUROPE CHLAMYDIA DIAGNOSIS AND TREATMENT MARKET SIZE, 2020-2027 ($ MILLION)
  • 25. INDIA CHLAMYDIA DIAGNOSIS AND TREATMENT MARKET SIZE, 2020-2027 ($ MILLION)
  • 26. CHINA CHLAMYDIA DIAGNOSIS AND TREATMENT MARKET SIZE, 2020-2027 ($ MILLION)
  • 27. JAPAN CHLAMYDIA DIAGNOSIS AND TREATMENT MARKET SIZE, 2020-2027 ($ MILLION)
  • 28. SOUTH KOREA CHLAMYDIA DIAGNOSIS AND TREATMENT MARKET SIZE, 2020-2027 ($ MILLION)
  • 29. REST OF ASIA-PACIFIC CHLAMYDIA DIAGNOSIS AND TREATMENT MARKET SIZE, 2020-2027 ($ MILLION)
  • 30. REST OF THE WORLD CHLAMYDIA DIAGNOSIS AND TREATMENT MARKET SIZE, 2020-2027 ($ MILLION)
目次
Product Code: OMR2018329

Global Chlamydia Diagnosis and Treatment Market Research By Diagnosis Methods (Chlamydia Culture, Urine Culture, Enzyme Immunoassays and Nucleic Acid Amplification Test), By Treatment Approach (Oral Antibiotics and Injectable), and By End-User (Hospitals, Diagnostic Centers And Research Institutions) Forecast Period (2021-2027)

The global chlamydia diagnosis and treatment market is growing at a considerable CAGR of 6.0% during the forecast period. Change in lifestyle is one of the prime factors affecting and driving the market. Increasing adoption of point of care diagnostic tests, awareness created regarding chlamydia diagnosis and treatment by government among others is also estimated to be the key factors that are contributing significantly towards the growth of the market. However, low awareness in emerging countries along with preventive measure for STDs are some major factors constraints that are hindering the growth of the global chlamydia diagnosis and treatment market across the globe.

Further, technology advancement such as micro-fluid diagnostic is one of the main factors that are creating opportunity for the market. New product launches and acquisition in the market are likely to drive the growth of the global chlamydia diagnosis and treatment market. For instance, in January 2021, Hologic, Inc. which is one of the medical technology companies that primarily focuses on betterment of women health had set forth the acquisition of Somatex Medical Technologies Gmbh. The transaction for acquiring the company was around $64 million that will support the Hologic, Inc. to diversify its portfolio for purpose of providing effective solution.

Impact of COVID-19 on the Global Chlamydia Diagnosis and Treatment Market

The global chlamydia diagnosis and treatment market is hardly hit by the COVID-19 pandemic since December 2019. The COVID-19 pandemic in the major economies had disrupted the manufacturing and transportation sector. Due to this COVID-19 pandemic it had led to disturbance in health clinics and diagnostic centers especially in the US. However, various strategies in STI are being adopted for providing the effective treatment that can improve the market growth.

Segmental Outlook

The market is segmented based on diagnosis methods, treatment approach and end-user. Based on diagnosis methods, the market is segmented into chlamydia culture, urine culture, enzyme immunoassays and nucleic acid amplification test. By treatment approach, the market is segmented into oral antibiotics and injectable. Further, by end-user, market is segmented into hospitals, diagnostic centers and research institutions.

Global Chlamydia Diagnosis and Treatment Market Share by Treatment Approach 2020 (%)

Global Chlamydia Diagnosis and Treatment Market Share by Treatment Approach

Based on the treatment approach, oral antibiotics is having significant share in the market. oral antibiotics are mostly given to patient suffering from chlamydia and considered as an effective treatment option as well. According to National Health Service (NHS) more than 95% people suffering from this disease can be cured if they intake antibiotics rightly. Generally, two antibiotics are been prescribed for chlamydia that includes azithromycin and doxycycline. Azithromycin is a type of macrolide-type antibiotic that supports in restricting the growth of bacteria. Whereas doxycycline is considered for fighting bacteria in the body as it is a tetracycline antibiotic.

Regional Outlooks

The global chlamydia diagnosis and treatment market is analyzed based on the geographical regions that are contributing significantly towards the growth of the market. Based on the geography, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America held a considerable share in 2020 in the global chlamydia diagnosis and treatment market. Some factors that are boosting the market growth in North America are raising pervasiveness of disease and leading players present in the region. Additionally, increasing awareness in health care, growing research activities along with increased health care expenditure is some other factors that are promoting the growth of the market.

Global Chlamydia Diagnosis and Treatment Market, by Region 2021-2027

Global Chlamydia Diagnosis and Treatment Market, by Region

Asia-Pacific will have Considerable Growth in the Global Chlamydia Diagnosis and Treatment Market

Asia-Pacific region is expected to witness significant growth opportunities for the market. Increasing rate of infectious diseases along with technology development in emerging economies of the region are likely to drive the growth of the regional market. Further, due to health availability, rising health care expenditure along with increasing demand for rapid diagnostic kits in India, China and South Korea are also some of the factors that are affecting and impacting the growth in this market.

Market Player Outlook

Key players of the global chlamydia diagnosis and treatment market are Abbott, binx health Inc., Diazyme Laboratories, Inc., Hologic, Inc., and F. Hoffmann-La Roche Ltd., among others. To survive in the market, these players adopt different marketing strategies such as product launches. For instance, in October 2020, Evofem Biosciences, Inc. had set forth the enrollment of its first patient in order to evaluate the safety and efficacy of EVO100 in its phase 3 clinical trials for preventing urogenital chlamydia and gonorrhea in women.

In July 2019, Nurx Inc. had introduced its 3 new testing kits in its sexually transmitted infection (STI) testing option. The STI home testing kit will support in testing for HIV, Chlamydia, and gonorrhea along with syphilis. Moreover, this kit could be easily received by filling up an online questionnaire and it comes at home conveniently with all instructions and tools.

In May 2019, F. Hoffmann-La Roche Ltd. received approval from the U.S. Food and Drug Administration (FDA) for its Cobas TV/MG test in order to use the Cobas 6800/8800 system. This system would support in proper progressing through laboratories by single patient sample as a combination of Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV), and Mycoplasma genitalium (MG) in order to get information for diagnosis of STD and for betterment in patient care.

The Report Covers

Market value data analysis of 2020 and forecast to 2027.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global chlamydia diagnosis and treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Chlamydia Diagnosis and Treatment Industry
  • Recovery Scenario of Global Chlamydia Diagnosis and Treatment Industry
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of Covid-19 on Key Players

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Chlamydia Diagnosis and Treatment Market by Diagnosis Methods
    • 5.1.1. Chlamydia Culture
    • 5.1.2. Urine Culture
    • 5.1.3. Enzyme Immunoassays
    • 5.1.4. Nucleic Acid Amplification Test
  • 5.2. Global Chlamydia Diagnosis and Treatment Market by Treatment Approach
    • 5.2.1. Oral Antibiotics
    • 5.2.2. Injectable
  • 5.3. Global Chlamydia Diagnosis and Treatment Market by End-User
    • 5.3.1. Hospitals
    • 5.3.2. Diagnostic Centers
    • 5.3.3. Research Institutions

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. South Korea
    • 6.3.5. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Abbott
  • 7.2. Aetna Inc.
  • 7.3. Anthem, Inc
  • 7.4. binx health, inc.
  • 7.5. Bio-Rad Laboratories, Inc.
  • 7.6. DiaSorin S.p.A
  • 7.7. Diazyme Laboratories, Inc.
  • 7.8. Evofem Biosciences, Inc.
  • 7.9. F. Hoffmann-La Roche Ltd
  • 7.10. Hologic, Inc.
  • 7.11. Laboratory Corporation of America
  • 7.12. NURX Inc.
  • 7.13. Quidel Corp.
  • 7.14. Siemens
  • 7.15. Synapse Diagnostics PVT LTD
  • 7.16. Tosoh Corp.
  • 7.17. Trinity Biotech
  • 7.18. Thermo Fisher Scientific Inc.